Benefits of using vaccines out of the cold chain: Delivering Meningitis A vaccine in a controlled temperature chain during the mass immunization campaign in Benin

BACKGROUND: In October 2012, the Meningococcal A conjugate vaccine MenAfriVac was granted a label variation to allow for its use in a controlled temperature chain (CTC), at temperatures of up to 40 °C for not more than four days. This paper describes the first field use of MenAfriVac in a CTC during...

Descripción completa

Detalles Bibliográficos
Autores principales: Zipursky, Simona, Djingarey, Mamoudou Harouna, Lodjo, Jean-Claude, Olodo, Laifoya, Tiendrebeogo, Sylvestre, Ronveaux, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355207/
https://www.ncbi.nlm.nih.gov/pubmed/24559895
http://dx.doi.org/10.1016/j.vaccine.2014.01.038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355207/
https://www.ncbi.nlm.nih.gov/pubmed/24559895
http://dx.doi.org/10.1016/j.vaccine.2014.01.038

Ejemplares similares